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Multiple Myeloma (MM) is one of the B-cell malignan-
cies with a poor prognosis, characterized by the clonal
expansion of neoplastic plasma cells within the bone
marrow, elevated serum immunoglobulin, and osteolytic
bone disease. The first pathogenic step is a premalignant
monoclonal gamopathy of undetermined significance
(MGUS). With progression of MGUS to myeloma, com-
plex genetic/epigenetic events occur in the neoplastic
plasma cell, and in the bone marrow microenvironment.
The resultant interactions of myeloma cells, bone mar-
row stromal cells, and microvessels contribute to persis-
tence of the tumour and resistance to drugs. Matrix
metalloproteinases (MMPs) play a critical rule in bone
remodeling (osteolitic lesions) and tumor invasion, and
could be a new therapeutic target in MM.
The aim of this study is to evaluate the therapeutic
potential of a metalloproteinase inhibitor, batimastat
(BB-94), in a multiple myeloma cell line in culture.
For this purpose a MM cell line, the NCI-H929
[H929] cells were cultured in absence and presence of
different concentrations of the MMP inhibitor, BB-94,
during different periods of time. Cell viability and death
was determined by the alamar blue assay and by flow
cytometry using the annexin V/propidium iodide
incorporation.
Our preliminary results show that BB-94 has, along a
broad concentration range, an antiproliferative effect in
MM cells that is accompanied by a cytotoxic effect as
results of increased apoptosis levels as the concerntratio
increases from 1 to 5µM.
This study suggests that batimastat could be a new
therapeutic approach in multiple myeloma in
monotherapy.
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